SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (18858)4/7/1998 10:33:00 PM
From: Hippieslayer  Respond to of 32384
 
Panretin is not a blockbuster drug. It's target population is small and will not generate, imo, a large amount of revenues for LGND. That may be why the STreet yawns when LGND comes out with news about this particular drug. It's my belief that lgnd will only significantly move once it makes money and once Targretin either show that it works well against Breast cancer in clinicals or once Targretin itself is approved.



To: tonyt who wrote (18858)4/7/1998 10:41:00 PM
From: John O'Neill  Respond to of 32384
 
toynt.........The stock has been consolidating and fluctuating a lot because the fundamentals were unclear at that time, That's why the price is about the same as it was 18 mos ago.

Given the time you've devoted to posting.....you "owe it" to your self
to go long with all you got. You may still have a chance, given the market weakness.
JO


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News